Clinical trial · no report yet · Phase 2
NCT02538198
Lenalidomide Maintenance in Plasma Cell Myeloma
- NCT02538198 ↗
- Active not recruiting
- Memorial Sloan Kettering Cancer Center
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Lenalidomide Maintenance in Plasma Cell Myeloma
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Plasma Cell Myeloma
- Interventions
- Lenalidomide
- Arms
- Lenalidomide · Experimental
- Enrollment
- 108
- Primary outcomes
- progression-free survival
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 31, 2015
- Primary completion
- Aug 2027 (estimated)
- Results posted
- No
- Registry record
- NCT02538198 · updated Sep 25, 2026
Publications
linked from the registry- Diamond B, Korde N, Lesokhin AM, Smith EL, Shah U, Mailankody S, Hultcrantz M, Hassoun H, Lu SX, Tan C, Rustad EH, Maura F, Maclachlan K, Peterson T, Derkach A, Devlin S, Landau HJ, Scordo M, Chung DJ, Shah GL, Lahoud O, Thoren K, Murata K, Ramanathan L, Arcila ME, Ho C, Roshal M, Dogan A, Giralt SA, Landgren O. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021 Jun;8(6):e422-e432. doi: 10.1016/S2352-3026(21)00130-7. PubMed 34048681